Stockreport

Allakos Announces Results from a Phase 1 Study of Subcutaneously Administered Lirentelimab (AK002)

Allakos Inc.  (ALLK) 
Last allakos inc. earnings: 11/12 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.allakos.com/investor-relations
PDF -- Subcutaneous formulation of lirentelimab was safe and well tolerated and demonstrated sustained eosinophil suppression supporting once monthly dosing -- -- Managemen [Read more]